<DOC>
	<DOCNO>NCT02804646</DOCNO>
	<brief_summary>The purpose study discuss efficacy safety recombinant human endostatin ( endostar ) durative intravenous transfusion combine pemetrexed plus cisplatin carboplatin first-line treatment advance lung adenocarcinoma wild-type EGFR ALK-negative , compare chemotherapy without endostar .</brief_summary>
	<brief_title>Endostar Durative Transfusion Combined With Chemotherapy Treatment Advanced Lung Adenocarcinoma</brief_title>
	<detailed_description>With progress molecular biology translational medical research , treatment advance non-small cell lung cancer go era personalize medicine . Lung adenocarcinoma account 50 % non-small cell lung cancer.In recent year , although individualize targeted therapy lung adenocarcinoma progress leaps bound , research wild-type EGFR ALK-negative lung adenocarcinoma extremely lag , lack clinically effective target drugs.As time go , almost EGFR-TKI treatment lung adenocarcinoma resistant one day , patient need treatment , chemotherapy.Currently , chemotherapy still main treatment advance lung adenocarcinoma EGFR wild-type unkown.Many research report : endostar combine chemotherapy patient advance NSCLC significantly improve patient 's RR , TTP increase adverse effect chemotherapy.Recently , endostar durative intravenous transfusion widely accept use lower toxicity.The purpose study discuss efficacy safety endostard durative intravenous transfusion combine chemotherapy.In study , Patients Ⅲb/Ⅳ lung adenocarcinoma divide two group randomly , one group treat endostar durative intravenous transfusion combine chemotherapy , group chemotherapy pemetrexed plus cisplatin carboplatin only.In end , PFS , ORR , DCR OS compare two group .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 ) histologically confirm ( patient receive single sputum cytology diagnosis ) nonsmall cell lung cancer patient , wildtype EGFR ALKnegative ; 2 ) According IASLC2009 new TNM staging lung cancer stage ⅢB Ⅳ , previously untreated relapse 1 year lung cancer resection ; 3 ) least one evaluable lesion , accord version 1.1 standard accordance judgment RECIST ( long diameter spiral CT least 10mm , regular CT long diameter least 20mm ) ; 4 ) Male female , age 18 75 year ; 5 ) ECOG PS 0 1 ; 6 ) expect survival least 3 month ; 7 ) adequate hematological function : absolute neutrophil count ( ANC ) least 2×10^9/L platelet count least 100×10^9/L hemoglobin least 9 g/dL ; 8 ) adequate liver function : total bilirubin less upper limit normal ( ULN ) ; AST ALT less 2.5 time upper limit normal ( ULN ) ; alkaline phosphatase less 5 time upper limit normal ( ULN ) ; 9 ) adequate renal function : serum creatinine less upper limit normal ( ULN ) calculate creatinine clearance least 60 mL/min ; 10 ) ECG normal , nonhealing wound body ; 11 ) receive previous treatment anticancer drug , receive previous nonmetastatic tumor adjuvant neoadjuvant chemotherapy , start study treatment end 6 month ; 12 ) conduct previous surgery patient require study treatment start four week , patient recover ; 13 ) intact uterus woman prior enrollment study must negative pregnancy test result ( unless already 24 month amenorrhea ) within 28 day . If pregnancy test first administration seven day , urine pregnancy test require authentication ( le 7 day first dose ) ; 14 ) previous biological agent , particularly E.coli genetically engineer product without serious allergic reaction ; 15 ) sign informed consent . 1 ) pregnancy , breastfeed woman , female patient childbearing potential take contraceptive measure ; 2 ) exist severe acute infection control ; purulent chronic infection , delay heal wound ; 3 ) original severe heart disease , include congestive heart failure , uncontrolled highrisk arrhythmia , unstable angina , myocardial infarction , severe heart valve disease resistant hypertension ; 4 ) suffer neurological psychiatric disease mental disorder easy control , poor compliance , describe treatment responder ; primary brain central nervous metastasis disease control , significant cranial hypertension neuropsychiatric symptom ; 5 ) bleeding tendency ; 6 ) researcher believe patient participate present trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Recombinant human endostatin ( Endostar )</keyword>
	<keyword>Durative transfusion</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>